Med. praxi. 2020;17(4):253-257 | DOI: 10.36290/med.2020.048

Current situation in fighting HPV infection

doc. MUDr. Tomáš Fait, Ph.D.
Gynekologicko-porodnická klinika 2. LF UK a FN Motol, Praha

Human papillomaviruses (HPVs) are the most significant causative factor in the development of cervical cancer as well as other malignant and benign lesions of the female and male genital organs and, in part, of other transition zones between squamous and columnar epithelia. Prevention of acquiring this infection ultimately results in primary prevention of all these lesions. Primary prevention by means of vaccination with quadrivalent, bivalent, and, most recently, nonavalent HPV vaccine exhibits high efficacy against the types of HPV included as well as excellent safety. Moreover, population-based data show a reduction in HPV-associated lesions after vaccination initiation. Two-dose schedules, provision of partial reimbursement for the nonavalent vaccine, and gender equalization of boys might help achieve a higher coverage of the target population in the Czech Republic.

Keywords: human papillomaviruses, HPV-associated cancers, HPV vaccine, vaccination of boys.

Published: September 25, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fait T. Current situation in fighting HPV infection. Med. praxi. 2020;17(4):253-257. doi: 10.36290/med.2020.048.
Download citation

References

  1. Bosch FX, Castellsague X, Sanjosé S. HPV and cervical cancer: screening or vaccination. Br J of Cancer 2008, 98: 15-21. Go to original source... Go to PubMed...
  2. Fait T, Vrablík M, Češka R, a kol. Preventivní medicína. Praha: Maxdorf Jessenius 2008: s. 554.
  3. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003; 127: 930-934. Go to original source...
  4. Muñoz N, Bosch FX, Castellsagué X, et al. Against which human papillomavirus types shall we vaccinate and screen? Int J Cancer. 2004; 111: 278-285. Go to original source...
  5. Piňos I. Nejčastější příčiny selhání v prevenci karcinomu děložního hrdla a její následky. Gyn por 2017, 5: 283-284.
  6. Sláma J. Současné limity prevence karcinomu děložního hrdla v České republice. Čes. Gynek. 2017; 82(6): 482-486.
  7. Ngo O, Chloupková R, Ambrožová M, a kol. Vyhodnocení adresného zvaní českých občanů do screeningových programů. Čas lek čes 2019; 158(3-4): 147-150.
  8. Herbeck G, Ondruš J, Dvořák V, Mortakis A. Atlas kolposkopie. Maxdorf 2011: 514 s.
  9. Syrjanen KJ. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Reprod Biol 1996; 65(1): 45-53. Go to original source...
  10. Wong JH, Sze SCW, Ng TB, et al. Apoptosis and Anti-cancer Drug Discovery: The Power of Medicinal Fungi and Plants. Curr Med Chem. 2018; 25(40): 5613-5630. Go to original source...
  11. Palacios S, Losa F, Dexeus D, Cortés J. Beneficial effects of a Coriolus versicolor-based vaginal gel on cervical epithelization, vaginal microbiota and vaginal health: a pilot study in asymptomatic women. BMC Womens Health. 2017; 17(1): 21-27. Go to original source...
  12. Kang WD, Choi HS, Kim SM. Is vaccination with Q-HPV vaccine after loop electosurgical excision procedure effective in preventing recurrence in patients with high grade CIN? Gynecol Oncol 2013; 130: 264-268. Go to original source...
  13. Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project. Gynecol Oncol 2018; 151: 229-234. Go to original source...
  14. Fait T, Dvořák V, Skřivánek A, et al. Epidemiologie genitálních bradavic mezi ženami v České republice. Čes Gynek 2012; 77(4): 360-363.
  15. Grennan D. Genital warts. JAMA 2019; 321(5): 520. Go to original source... Go to PubMed...
  16. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment and prevention. Clin Infect Dis 2002, 35(Suppl. 2): S210-S224. Go to original source...
  17. Gallagher TQ, Derkay CS. Recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg 2008; 16: 645-655. Go to original source...
  18. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012, 15; 307(7): 693-703. Go to original source...
  19. Palefsky JM, Giuiliano AR, Goldstone S, et al. HPV valine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365: 1567-1585. Go to original source...
  20. Fairley CK, Hocking JS, Gurrin LC, et al. Rapid decline in presentation of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009, 85: 499-502. Go to original source... Go to PubMed...
  21. Fait T, Pilka R, Dvořák V. Nonavalentní HPV vakcína - nová generace očkování proti HPV. Ces Gynek 2015; 80(6): 397-400.
  22. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13(1): 100-110. Go to original source...
  23. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012; 12(10): 781-789. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.